Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple myeloma
- Trial result
Multiple myeloma
Linvoseltamab (BCMA×CD3) + Bortezomib Delivers 79% ORR and 6-mo DOR 90% in Triple-Class-Exposed R/R MM
Linvoseltamab, a bispecific antibody linking BCMA and CD3, was paired with proteasome-inhibitor bortezomib in the phase 1b LINKER-MM2 dose-escalation cohort (NCT05137054). Twenty-two heavily pre-treated…
NCT05137054 - Trial result
Multiple myeloma
Etentamig BCMA×CD3 Bispecific Hits 66% ORR with Half-the-Usual CRS in Triple-Class–Exposed Myeloma
Etentamig, a bivalent BCMA×CD3 T-cell engager engineered with low-affinity CD3 and a silenced Fc, was pooled across two Phase 1/1b studies (NCT03933735; NCT05650632) in relapsed/refractory multiple myeloma after ≥3…
NCT03933735 - Trial result
Multiple myeloma
Daratumumab + Carfilzomib/Lenalidomide/Dex Beats KRd Alone for Deep Remission in Newly Diagnosed Myeloma
Daratumumab, an anti-CD38 IgG1κ antibody, was added to the KRd triplet (Carfilzomib/Lenalidomide/Dex) in the randomized phase 2 ADVANCE trial (n=306 NDMM; transplant-eligible and ineligible). In 306 patients with…
- Trial result
Multiple myeloma
Elranatamab + Daratumumab/Lenalidomide Logs 92% Confirmed ORR in Transplant-Ineligible NDMM
In part 1 (dose level G) of the phase 3 MagnetisMM-6 trial (NCT05623020), 37 newly diagnosed, transplant-ineligible myeloma patients received subcutaneous elranatamab 76 mg Q4W plus daratumumab and lenalidomide. At…
NCT05623020 - Trial result
Multiple myeloma
JNJ-5322 Trispecific BCMA/GPRC5D/CD3 Antibody Delivers 100% ORR in Target-Naïve R/R Myeloma
JNJ-79635322 (JNJ-5322) is an off-the-shelf trispecific antibody that co-engages BCMA and GPRC5D on myeloma cells while recruiting CD3⁺ T cells. In the first-in-human phase 1 dose-escalation/optimization trial…
NCT05652335 - New trial
Multiple myeloma
Phase 2 trial: Elranatamab, a BCMA/CD3 bispecific mAb in combination for multiple myeloma
This phase 2 study evaluates Elranatamab with lenalidomide and dexamethasone as first-line therapy in newly diagnosed multiple myeloma patients at University of Miami. The trial compares this ERd combination against…
NCT06997081 - New trial
Multiple myeloma
Phase 1b/2a Study of Mezigdomide Cereblon E3 Ligase Modulator & Elranatamab BCMA/CD3 Bispecific
Celgene sponsors this multicenter, open‐label trial evaluating mezigdomide with elranatamab (plus dexamethasone) to establish the recommended dose and safety in relapsed/refractory multiple myeloma across 2nd–5th…
NCT06988488 - New trial
Multiple myeloma
Phase 2 trial of talquetamab, a GPRC5D x CD3 bispecific antibody, in multiple myeloma.
This trial evaluates a response-adaptive consolidation strategy where MRD-positive patients after frontline induction receive talquetamab, with a switch to teclistamab if MRD negativity is not achieved. The study,…
NCT06993675 - New trial
Multiple myeloma
Phase II Study of Talquetamab (GPRC5D/CD3 Bispecific) in Post-Transplant Multiple Myeloma Maintenance
Stanford University is launching an open-label, non-randomized Phase II study evaluating talquetamab—a bispecific antibody targeting GPRC5D and CD3—as monotherapy in cycle 1 and in combination with lenalidomide from…
NCT06461988 - Trial result
Multiple myeloma
Daratumumab-Enhanced Regimen Elevates Outcomes in Older NDMM Patients
Pooled data from the GRIFFIN and PERSEUS studies in transplant-eligible patients aged ≥65 years indicate that adding daratumumab to VRd induction/consolidation followed by daratumumab–lenalidomide maintenance…
- New trial
Multiple myeloma
Phase 1 Trial: SX-682 Combination with Standard of Care in Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute is evaluating SX-682—a CXCR1/2 inhibitor—in combination with carfilzomib, daratumumab-hyaluronidase, and dexamethasone for patients with secretory multiple myeloma that has relapsed or…
NCT06622005 - New trial
Multiple myeloma
Phase 2 Study of Elranatamab Plus Isatuximab in Relapsed and Refractory Multiple Myeloma
MGH is launching an open-label phase 2 trial evaluating subcutaneous elranatamab in combination with investigational isatuximab for RRMM patients after at least two prior therapies, including IMiDs and proteasome…
NCT06832865 - Trial result
Multiple myeloma
ISB 2001, a Novel Trispecific Antibody, Shows Robust Activity in Relapsed/Refractory Multiple Myeloma
In this first-in-human phase 1 study, 21 heavily pre-treated relapsed/refractory multiple myeloma (RRMM) patients across 7 dose levels (5–1200 μg/kg) received weekly subcutaneous injections of ISB 2001 with step-up…
- New trial
Multiple myeloma
Phase II Study of Elranatamab as Maintenance Therapy Post Cilta-cel in High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute is evaluating whether maintenance therapy with elranatamab, initiated 3–6 months after cilta-cel infusion, can extend progression-free survival in patients with…
NCT06947083
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.